Authors
Latest:
Evaluating Immunotherapy in Nonmetastatic Colorectal CancerDr. Sinicrope reviews the phase III ATOMIC trial, which is testing standard chemotherapy alone or in combination with the anti–PD-L1 antibody atezolizumab as adjuvant therapy in a subset of colon cancer patients.
Latest:
Dr. Oratz on PARP Inhibitors to Treat Patients With Breast CancerCancer Network spoke with Ruth Oratz, MD, a medical oncologist at NYU Langone Perlmutter Cancer Center in New York City, about the use of PARP inhibitors for breast cancer.
Latest:
Using Cannabis as a Palliative Treatment in Patients With CancerAhead of the ASCO Annual Meeting, we discuss the use of cannabis as a palliative treatment in patients with cancer with Claude Cyr, MD.
Latest:
Managing Cytokine Release Syndrome in Patients on CAR T-Cell TherapyAhead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
Latest:
Considerations When Initiating Neratinib for Breast Cancer: How to Prevent and Treat DiarrheaAn oncology pharmacist discusses how to prevent and treat diarrhea in patients taking neratinib for breast cancer.
Latest:
Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?In this Point/Counterpoint, Drs. Bhat and Punnen argue that active surveillance can be beneficial for patients with intermediate-risk prostate cancer.
Latest:
Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?In this Point/Counterpoint, Drs. Bhat and Punnen argue that active surveillance can be beneficial for patients with intermediate-risk prostate cancer.
Latest:
Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?In this Point/Counterpoint, Drs. Madueke and Abern argue that active surveillance should not currently be considered for patients with intermediate-risk prostate cancer.
Latest:
Breaking New Ground in the Treatment of Advanced Endometrial CancerDr. Makker summarizes the standard of care for the treatment of advanced endometrial cancer, with a look forward to the multitude of clinical trials evaluating novel therapy combinations that are currently enrolling patients or underway.
Latest:
Suicide in Patients With Cancer: Identifying the Risk FactorsThis article reviews the prevalence of suicide in patients with cancer, risk factors, related conditions, and interventions to identify and treat suicidal patients.
Latest:
Suicide in Patients With Cancer: Identifying the Risk FactorsThis article reviews the prevalence of suicide in patients with cancer, risk factors, related conditions, and interventions to identify and treat suicidal patients.
Latest:
Personality Disorders in Patients with CancerPersonality disorders become exacerbated under stressful cancer-related situations and may lead to adverse consequences and outcomes.
Latest:
Suicide in Patients With Cancer: Identifying the Risk FactorsThis article reviews the prevalence of suicide in patients with cancer, risk factors, related conditions, and interventions to identify and treat suicidal patients.
Latest:
Preventing Gastric Cancer Development by Inhibiting the Virulence of H. pylori InfectionDr. Wilson discusses a chemopreventive drug that may help prevent gastric cancer by acting directly on H. pylori.
Latest:
Progressive Red-to-Violaceous Papules and Plaques on the Neck and Abdominal Skin of a 70-Year-Old WomanA 70-year-old woman developed red-to-violaceous papules, plaques, and nodule- like skin lesions several months prior to her presentation. The skin lesions mostly involved her lower neck and abdominal area. What is the most likely diagnosis?
Latest:
Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal CancerIn this article, we review the characteristics of the BRAF mutation and the evolving strategies for managing BRAF-mutant metastatic colorectal cancer.
Latest:
Clinical Trials in Progress: COBRAPhase 2/3 Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA): a first-in-kind trial seeks to provide level 1 evidence in evaluating the role of ctDNA as a guide for clinicians in the decision to administer adjuvant chemotherapy to patients with stage IIA colon cancer (NRG GI-005) (NCT04068103).
Latest:
Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal CancerIn this article, we review the characteristics of the BRAF mutation and the evolving strategies for managing BRAF-mutant metastatic colorectal cancer.
Latest:
Dr. Cascone on Combination Checkpoint Blockade for Early-Stage Non–Small-Cell Lung CancerCancer Network spoke with Tina Cascone, MD, of MD Anderson Cancer Center, at ASCO 2019 about combination checkpoint blockade in the pre-surgical setting for early-stage NSCLC.
Latest:
Dr. Chiara Cremolini on the Updated Results of the TRIBE2 Study for Unresectable Colorectal CancerCancer Network spoke with Chiara Cremolini, MD, about the updated results of the phase III randomized strategy study TRIBE2, which looked at the first- and second-line treatment of unresectable metastatic colorectal cancer.
Latest:
Dr. Hala Borno on Addressing Disparities in Access to Prostate Cancer CareCancer Network spoke with Hala Borno, MD, of the University of California, San Francisco, about addressing the disparities in access to clinical trials and treatments for patients with prostate cancer.
Latest:
Incidence of Non-Melanoma Skin Cancer Tallies Biggest Change From 2016 to 2017The Global Burden of Disease 2017 study found non-melanoma skin cancer to be the biggest increase in incidence worldwide.
Latest:
Dr. Arbour on the Latest Data for Checkpoint Inhibitors for Lung Cancer in 2019Cancer Network spoke with Kathryn Cecilia Arbour, MD, of Memorial Sloan-Kettering Cancer Center, about the most recent research on checkpoint inhibitors in oncology.
Latest:
Dr. Yoland Catherine Antill on Results of the PHAEDRA TrialCancer Network spoke with Yoland Catherine Antill, MD, of Cabrini Health, about the phase II PHAEDRA trial, which tested the activity of durvalumab in advanced endometrial cancer according to mismatch repair status.
Latest:
Dr. Jason Westin on Combination Targeted Therapy Prior to Chemotherapy for DLBCLCancer Network spoke with Jason Westin, MD, of MD Anderson Cancer Center, about the Smart Start trial, which showed that a combination of targeted therapy prior to chemotherapy proved to be effective in patients with DLBCL.
Latest:
Dr. Paul Chapman on the Choice to Pursue Adjuvant Immunotherapy for Melanoma PatientsCancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan Kettering Cancer Center, about pursuing adjuvant immunotherapy for patients with melanoma.
Latest:
Key Takeaways From ITC Analysis of First-Line Dual-IO Treatments in Advanced MelanomaPanelists discuss how the ITC analysis of first-line dual-IO treatments in advanced melanoma highlights the potential for nivolumab plus relatlimab to offer similar efficacy to nivolumab plus ipilimumab, with a more favorable safety profile, particularly in terms of lower rates of severe immune-related adverse events.
Latest:
Dr. Anna Pavlick on Dendritic Cells vs Montanide in Melanoma Patients in RemissionCancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide.
Latest:
Dr. Thomas Gajewski on Analyzing the Tumor Microenvironment to Guide Immunotherapy in MelanomaCancer Network spoke with Thomas Gajewski, MD, PhD, of the University of Chicago Medical Center, about analyzing the tumor microenvironment to guide immunotherapy in melanoma.
